Xconomy’s Digital Events →
Tom Dubensky, the chief scientist at Immune Design, filled in for CEO Steve Reed, who wasn’t feeling well.
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.